Literature DB >> 20331975

Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 in gastric cancer.

Ruizhe Shen1, Shen Pan, Shengjian Qi, Xiaolin Lin, Shidan Cheng.   

Abstract

High levels of SOX4 expression have been found in a variety of human cancers, such as lung, brain and breast cancers. However, the expression of SOX4 in gastric tissues remains unknown. The SOX4 expression was detected using immunohistochemical staining and semi-quantitative RT-PCR, and our results showed that SOX4 was up-regulated in gastric cancer compared to benign gastric tissues. To further elucidate the molecular mechanisms underlying up-regulation of SOX4 in gastric cancers, we analyzed the expression of microRNA-129-2 (miR-129-2) gene, the epigenetic repression of which leads to overexpression of SOX4 in endometrial cancer. We found that up-regulation of SOX4 was inversely associated with the epigenetic silencing of miR-129-2 in gastric cancer, and restoration of miR-129-2 down-regulated SOX4 expression. We also found that inactivation of SOX4 by siRNA and restoration of miR-129-2 induced apoptosis in gastric cancer cells. 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20331975     DOI: 10.1016/j.bbrc.2010.03.121

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  70 in total

1.  Aberrant hypermethylation of miR-9 genes in gastric cancer.

Authors:  Kuo-Wang Tsai; Yu-Lun Liao; Chew-Wun Wu; Ling-Yueh Hu; Sung-Chou Li; Wen-Ching Chan; Meng-Ru Ho; Chun-Hung Lai; Hsiao-Wei Kao; Wen-Liang Fang; Kuo-Hung Huang; Wen-chang Lin
Journal:  Epigenetics       Date:  2011-10-01       Impact factor: 4.528

2.  Upregulation of miR-129-5p affects laryngeal cancer cell proliferation, invasiveness, and migration by affecting STAT3 expression.

Authors:  Na Shen; Xinsheng Huang; Jun Li
Journal:  Tumour Biol       Date:  2015-08-29

3.  Increased expression of SOX4 is a biomarker for malignant status and poor prognosis in patients with non-small cell lung cancer.

Authors:  Dingmiao Wang; Ting Hao; Yang Pan; Xiaowei Qian; Daixing Zhou
Journal:  Mol Cell Biochem       Date:  2015-01-08       Impact factor: 3.396

4.  Demethylation-mediated miR-129-5p up-regulation inhibits malignant phenotype of osteogenic osteosarcoma by targeting Homo sapiens valosin-containing protein (VCP).

Authors:  Xin Hua Long; Yun Fei Zhou; Ai Fen Peng; Zhi Hong Zhang; Xuan Yin Chen; Wen Zhao Chen; Jia Ming Liu; Shan Hu Huang; Zhi Li Liu
Journal:  Tumour Biol       Date:  2015-01-08

5.  MiR-424 functions as a tumor suppressor in glioma cells and is down-regulated by DNA methylation.

Authors:  Chen Jin; Minhong Li; Yian Ouyang; Zhigang Tan; Yugang Jiang
Journal:  J Neurooncol       Date:  2017-05-15       Impact factor: 4.130

Review 6.  MicroRNA and signaling pathways in gastric cancer.

Authors:  Z Zhang; Z Li; Y Li; A Zang
Journal:  Cancer Gene Ther       Date:  2014-07-25       Impact factor: 5.987

7.  miR-129-3p, as a diagnostic and prognostic biomarker for renal cell carcinoma, attenuates cell migration and invasion via downregulating multiple metastasis-related genes.

Authors:  Xuanyu Chen; Anming Ruan; Xuegang Wang; Weiwei Han; Rong Wang; Ning Lou; Hailong Ruan; Bin Qiu; Hongmei Yang; Xiaoping Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2014-05-07       Impact factor: 4.553

8.  MYO5B is epigenetically silenced and associated with MET signaling in human gastric cancer.

Authors:  Wenjie Dong; Liping Wang; Ruizhe Shen
Journal:  Dig Dis Sci       Date:  2013-03-02       Impact factor: 3.199

Review 9.  DNA methylation and microRNA dysregulation in cancer.

Authors:  Hiromu Suzuki; Reo Maruyama; Eiichiro Yamamoto; Masahiro Kai
Journal:  Mol Oncol       Date:  2012-08-10       Impact factor: 6.603

Review 10.  SOX4 is a potential prognostic factor in human cancers: a systematic review and meta-analysis.

Authors:  J Chen; H L Ju; X Y Yuan; T J Wang; B Q Lai
Journal:  Clin Transl Oncol       Date:  2015-08-07       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.